Research

Hormonal

Tirzepatide (TRZD) and other GLP-1R/GIPR agonists may exhibit anti-cancer properties by sensitizing cancer cells to chemotherapy, inducing apoptosis, and inhibiting proliferation via pathways like PI3K/Akt/mTOR and AMPK, particularly in pancreatic, breast, and colorectal cancers.

Current research shows that drugs like Liraglutide and Exenatide can kill cancer cells or make chemo work better in lab mice. However, there is no proof yet that Tirzepatide does this in humans. Do not use these drugs as a cancer treatment outside of clinical trials.

ModerateSupportsLOW confidence
Liraglutide (a GLP-1R agonist) treatment sensitized gemcitabine-resistant pancreatic cell line (PANC-1) to gemcitabine leading to inhibition of cell proliferation and activation of apoptosis... Exenatide similarly exerted its antiproliferative effect on breast cancer cells via the inhibition of NF-κB nuclear translocation
Samson Mathews Samuel et al. · Biomolecules · 2022

Why this rating

Based on in vitro and xenograft mouse models; no human clinical trials for cancer treatment with TRZD are reported.

Source

Tirzepatide—Friend or Foe in Diabetic Cancer Patients?

Samson Mathews Samuel et al. · Biomolecules · 2022

DOI 10.3390/biom12111580

narrative_reviewCited 20×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →